Molecular Therapy: Methods & Clinical Development (Sep 2022)

Impact of genetically modified organism requirements on gene therapy development in the EU, Japan, and the US

  • Gentaro Tajima,
  • Seoan Huh,
  • Natalie Anne Schmidt,
  • Judith C. Macdonald,
  • Tobias Fleischmann,
  • Keith Merrell Wonnacott

Journal volume & issue
Vol. 26
pp. 74 – 83

Abstract

Read online

Advanced therapies are emerging as an important class of medicinal products; among these, gene therapies are advancing at an exceptional rate. However, one of the major challenges for gene therapies relates to the additional regulatory requirements for genetically modified organisms. In this paper, we provide an overview of the regulatory requirements for genetically modified organisms in the European Union, Japan, and the United States. We share our experience in managing these requirements and their impact on the adeno-associated virus gene therapies that are under development at Pfizer. Specifically, we discuss the relative complexity of the approval process and the impact of risk assessment expectations on the clinical development of genetically modified organisms. We also compare the regulatory processes and timelines of various regions based on our experience with adeno-associated viral vectors. Finally, we propose that genetically modified organisms, for which pathogenicity and replication competency are well controlled, should be regulated solely under medicinal product regulations and be exempt from additional requirements for genetically modified organisms. Even if an exemption is not implemented, it should still be possible to significantly reduce the sponsor and agency burden by simplifying and harmonizing documentation and data requirements as well as timelines for applications for genetically modified organisms.

Keywords